Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Medullary Thyroid Cancer Drug Profiles and Clinical Trials - Global Trends and Analysis Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 20 Nov 17

The "Medullary Thyroid Cancer Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H2 2017" report has been added to Research and Markets' offering.

Medullary Thyroid Cancer clinical trials report from provides comprehensive analysis and trends in global Medullary Thyroid Cancer disease clinical trials. The research work analyzes the evolution of Medullary Thyroid Cancer clinical trial trends across countries and regions.

The report focuses on drugs and therapies being evaluated for Medullary Thyroid Cancer treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Major drugs under development in Medullary Thyroid Cancer are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.

Scope of the Report:

  • Number of Medullary Thyroid Cancer clinical trials across regions - Asia and Oceania, Europe, Middle East Africa and Americas
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Medullary Thyroid Cancer
  • Both observational and interventional trials analyzed
  • Success rates of trials are analyzed
  • Trends in enrollment over the past ten years identified
  • Leading sponsors of Medullary Thyroid Cancer clinical trials worldwide are listed


Thyroid Cancer is categorized into three main types:

  • Differentiated Thyroid Cancer
    • Follicular
    • Papillary
    • Hurthle
  • Medullary Thyroid Cancer
    • Sporadic
    • Familial
  • Anaplastic Thyroid Cancer


  • Stage I - Tumor less than 2 cm
  • Stage II - Tumor between 2 cm and 4 cm
  • Stage III - Tumor more than 4 cm, or grown slightly beyond thyroid
  • Stage IVa - Tumor expands into nearby neck tissues/some lymph nodes/upper chest
  • Stage IVb - Tumor expands to spine/blood vessels
  • Stage IVC: Tumor might be spread to distant sites of body

Companies conducting Medullary Thyroid Cancer trials include:

  • Genzyme Europe B.V.
  • Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd
  • Loxo Oncology, Inc.
  • Blueprint Medicines Corporation
  • Exelixis
  • Sanofi
  • Stemcentrx
  • Bayer
  • Hutchison Medipharma Limited

For more information about this report visit

View source version on

Business Wire

Last updated on: 20/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.